ClinicalTrials.gg
CompletedNCT01896297Updated Nov 30, 2016Results posted

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

A Phase 4 interventional study of Pradaxa, dabigatran etexilate in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.

Enrollment
25th of 35
63 · median 174
Started
2013
with 3 others
Phase 4
22 of 35
none open now
Registered
12th of 35
by date
Lead sponsor
7 of 35
Boehringer Ingelheim

Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 25th largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 4, and was the 12th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing dabigatran in Atrial Fibrillation as a file.
02

Study summary

The goal of this study is to assess dabigatran pharmacokinetics in NVAF subjects with severe renal impairment defined as creatinine clearance between 15 and 30 mL/min calculated by Cockcroft-Gault formula.

The dabigatran etexilate dose of 75 mg BID was approved by the FDA for NVAF patients with severe renal impairment (CrCl 15-30 mL/min) , based on pharmacokinetic modeling and simulation.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with non-valvular atrial fibrillation with an indication for the anticoagulation therapy,
  • Subjects with severe renal function impairment defined as between 15 and 30 mL/min by Cockcroft-Gault formula,
  • Male and female patients, age =18 years at entry

Exclusion criteria

Exclusion criteria:

  • to Pradaxa (history of a serious reaction to Pradaxa, active pathological bleeding, patients with mechanical prosthetic heart valve),
  • \<15ml/min or patients with End Stage Renal Disease on dialysis,
  • Creatinine clearance >30 ml/min,
  • Pre-menopausal women (last menstruation less than one year prior to ) who are nursing or pregnant, or are of child bearing potential and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study. Acceptable methods of birth control include abstinence, tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, double barrier method and vasectomised partner,
  • Patients who are participating in another drug study,
  • Patients who have participated in another drug study within 6 weeks,
  • Patients considered unreliable by the investigator concerning the requirements for participating in the study, including a follow-up interview,
  • Any condition the investigator believes would not allow safe participation in the study,
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Other
    dabigatran etexilate

    75mg BID by oral

    Drug: Pradaxa, dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose

    Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss) taken at approximately 12 hours after the last dose (trough).

    Time frame: Immediately before the last drug administration, on day 8

  2. Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose

    Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose (C2,ss)

    Time frame: 2 hours after the last drug administration, on day 8

07

Results

Posted Nov 30, 2016

Participant flow

Participant flow — Overall Study
MilestoneDabigatran Etexilate
Started60
Completed59
Not completed1
Withdrew: Died in post treatment phase1

Outcome measures

PrimaryPre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose

Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss) taken at approximately 12 hours after the last dose (trough).

Time frame:
Immediately before the last drug administration, on day 8
Reported as:
Geometric mean · ng/mL
Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose
ng/mLDabigatran Etexilate
Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose155 ± 76.9
PrimaryConcentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose

Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose (C2,ss)

Time frame:
2 hours after the last drug administration, on day 8
Reported as:
Geometric mean · ng/mL
Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose
ng/mLDabigatran Etexilate
Concentration of Analyte in Plasma at Steady State at 2 Hours After Administration of the Last Dose202 ± 70.6

Adverse events

Collected over From first drug administration until 3 days after last drug administration, up to 18 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate—2/60 (3.3%)0/60 (0%)
Most frequent serious events
Most frequent serious events
EventDabigatran Etexilate
Acute myocardial infarctionCardiac disorders1/60
HyperkalaemiaMetabolism and nutrition disorders1/60

Baseline characteristics

Treated set (TS) which included all enrolled patients who were eligible to enter the trial, who were dispensed trial medication and were documented to have taken at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Dabigatran Etexilate
Mean83.35 ± 7.55
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate
Female36
Male24
08

Study locations

26 sites
  • 1160.173.002 Boehringer Ingelheim Investigational Site
    Hot Springs, Arkansas, United States
  • 1160.173.023 Boehringer Ingelheim Investigational Site
    Fremont, California, United States
  • 1160.173.032 Boehringer Ingelheim Investigational Site
    Moreno Valley, California, United States
  • 1160.173.034 Boehringer Ingelheim Investigational Site
    Oceanside, California, United States
  • 1160.173.025 Boehringer Ingelheim Investigational Site
    Salinas, California, United States
  • 1160.173.033 Boehringer Ingelheim Investigational Site
    San Pedro, California, United States
  • 1160.173.024 Boehringer Ingelheim Investigational Site
    Wilmington, Delaware, United States
  • 1160.173.010 Boehringer Ingelheim Investigational Site
    Washington, District of Columbia, United States
  • 1160.173.020 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.173.036 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1160.173.012 Boehringer Ingelheim Investigational Site
    Largo, Florida, United States
  • 1160.173.013 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 1160.173.005 Boehringer Ingelheim Investigational Site
    Columbus, Georgia, United States
  • 1160.173.018 Boehringer Ingelheim Investigational Site
    Springfield, Missouri, United States
  • 1160.173.019 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 1160.173.026 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 1160.173.027 Boehringer Ingelheim Investigational Site
    Neptune, New Jersey, United States
  • 1160.173.014 Boehringer Ingelheim Investigational Site
    Wilmington, North Carolina, United States
  • 1160.173.001 Boehringer Ingelheim Investigational Site
    Altoona, Pennsylvania, United States
  • 1160.173.008 Boehringer Ingelheim Investigational Site
    Pittsburgh, Pennsylvania, United States
  • 1160.173.037 Boehringer Ingelheim Investigational Site
    Lancaster, South Carolina, United States
  • 1160.173.030 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 1160.173.011 Boehringer Ingelheim Investigational Site
    Fort Worth, Texas, United States
  • 1160.173.006 Boehringer Ingelheim Investigational Site
    Live Oak, Texas, United States
  • 1160.173.021 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 1160.173.035 Boehringer Ingelheim Investigational Site
    Waukesha, Wisconsin, United States
09

References and documents

Publications

  • Martin JL, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):399-406. doi: 10.1177/1074248418769167. Epub 2018 Apr 25. PubMed 29695165 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2013
First posted
Jul 11, 2013
Start
Jul 2013
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Nov 30, 2016
Last update
Nov 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01896297
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Jul 2013
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Nov 30, 2016
Last update
Nov 30, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion